Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | HPGD | P15428 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | CA1 | P00915 | 2/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | CA4 | P22748 | 2/20 | 0.69 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.69 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.69 |
| ▸ | CA6 | P23280 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | GUSB | P08236 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthranilic Acid SCHEMBL3269367 | 0.86 | TRIM24 (0.60) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicyladehyde SCHEMBL27614253 | 0.85 | TRIM24 (0.95) | KDM4EALDH1A1CA1CA2CA4 | |
| Salicylic Acid SCHEMBL933093 | 0.84 | ALDH1A1 (0.82) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL1509155 | 0.83 | ALDH1A1 (1.00) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL29606432 | 0.83 | ALDH1A1 (1.00) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL29362663 | 0.83 | ALDH1A1 (1.00) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL17156443 | 0.83 | ALDH1A1 (1.00) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL8433746 | 0.83 | ALDH1A1 (1.00) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL1967 | 0.83 | ALDH1A1 (1.00) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL29360246 | 0.83 | ALDH1A1 (1.00) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3337474-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | Jenivision Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9820954-B2 | Quantitative peri-orbital application of ophthalmology drugs | JENIVISION INC. (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2017031137-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | JENIVISION INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170049734-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | JENIVISION INC. | 2017-02-23 | — | — | US | disclosed |
| US-20110059881-A1 | Sulphur Free Composition And Lubricant Composition And Methods Thereof | THE LUBRIZOL CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| EP-1587901-B1 | SULPHUR FREE COMPOSITION AND LUBRICANT COMPOSITION AND METHODS THEREOF | LUBRIZOL CORP (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20060247140-A1 | Sulphur free composition and lubricant composition and methods thereof | LUBRIZOL CORPORATION, THE | 2006-11-02 | — | — | US | disclosed |
| EP-1587901-A2 | SULPHUR FREE COMPOSITION AND LUBRICANT COMPOSITION AND METHODS THEREOF | THE LUBRIZOL CORPORATION (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004065530-A2 | SULPHUR FREE COMPOSITION AND LUBRICANT COMPOSITION AND METHODS THEREOF | THE LUBRIZOL CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049734-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | PTGIR, QDPR, PDE3A | KDM4E 1447/4885HPGD 69/4885ALDH1A1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.